Drugs from Eli Lilly and Boehringer Ingelheim grabbed the spotlight at the EASL congress on liver diseases, both showing promising results in metabolic dysfunction-associated steatohepatitis (MASH).

Today, EASL announced that Fischer has moved up to a new job: president. Fischer will oversee all marketing, commercial, and event operations, while working with CEO Henry Kerins on corporate ...

Company announcement - No. 39 / 2024Zealand Pharma Announces Financial Results for the First Half of 2024Very strong progress across R&D ...

Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) ...

At the EASL Congress in June, end-of-treatment data from the IM-PROVE I Phase 2a clinical trial showed 33.3% of patients ...

End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I ...

End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I ...

today announced that two scientific abstracts have been selected for poster presentation at the upcoming International Liver Congress™ 2024 hosted by the European Association for the Study of ...

EASL™ Congress 2024. Tobevibart monotherapy and combination therapy with elebsiran achieved high virologic response and ALT normalization in people living with the hepatitis delta virus after 12 ...

Israeli Prime Minister Benjamin Netanyahu should use his Wednesday speech to a joint meeting of Congress to seek a renewal of bipartisan American support for Israel that began when the U.S. became ...

Also at the EASL Congress in June, end-of treatment data was presented from the IM-PROVE II (AB-729-202) Phase 2a clinical trial evaluating the safety and immunogenicity of imdusiran, NA therapy ...